5 unknown. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 5 |
| Phase 2 | 2 | Unknown 2 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS XZB-0004 - AML, MDS | Phase 1 | Unknown | Xuanzhu Biopharmaceutical Co., Ltd. | 82 | 2023-02-01 | 2023-02-23 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| Study of APVO436 in Patients With AML or MDS APVO436 - AML, MDS | Phase 1 | Unknown | Aptevo Research and Development LLC | 136 | 2018-12-13 | 2022-02-10 |
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS Decitabine, Arsenic Trioxide - P53 Mutation, Myeloid Malignancy | Phase 1 | Unknown | Ruijin Hospital | 5 | 2018-01-10 | 2022-11-04 |
| A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS Deferasirox, Vitamin D and Azacitidine - MDS | Phase 1 / Phase 2 | Unknown | Groupe Francophone des Myelodysplasies | 50 | 2013-02-01 | 2018-01-10 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (2) · Arsenic Trioxide (1) · Decitabine (1) · Deferasirox (1) · Vitamin D (1)
Aptevo Research and Development LLC (1) · Ascentage Pharma Group Inc. (1) · Groupe Francophone des Myelodysplasies (1) · Ruijin Hospital (1) · Xuanzhu Biopharmaceutical Co., Ltd. (1)
China (2) · United States (2) · Belgium (1) · France (1)
Felipe Suarez, MD (1) · Olivier Hermine, MD (1) · Pierre Fenaux, MD (1) · Sujiang Zhang, MD, PhD (1) · Yifan Zhai, MD, PhD (1)